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The steroid regimen used most often is a 5-day course of oral (PO) pre dnisone or prednisolone. [5] [6] [7] How ever, some literature suggests that this regimen lacks consistent patient compliance [8] [9] [10] and has poor pala tability. 11 One study demonstrated that complete adherence to the full course of PO prednisone for pediatric asthma exacerbation was only 64%. 10 Another study found the fi lling rate of prednisone and prednisolone in a pediatric Medicaid population was as low as 45% after ED discharge and 56% after hospitalization. 12 A recent survey study determined that 88% of parents prefer a short 1-to 2-day course versus 5 days of steroids, and therefore a shorter medication course may improve overall adherence. 13 Although much has been pub lished on the equivalence of PO and intravenous (IV) corticosteroids in acute asthma exacerbations, [14] [15] [16] few studies have directly compared cor ticosteroid formulations. Due to the aforementioned issues with prednisone, dexamethasone has been studied as an alternative. Dexamethasone is a long-acting glu cocorticoid that has been used safely in children for treating con ditions such as croup. 17 It has a 36-to 72-hour half-life, compared with the 12-to 36-hour half-life of prednisone, and therefore requires fewer doses. [18] [19] [20] Furthermore, dexamethasone tastes better 11 and costs less in terms of unscheduled revisits. 21 Cross et al 22 published a brief over view of the literature examining the use of singledose dexamethasone for pedi atric asthma exacerbations in ambulatory care settings. Redman and Powell 23 also recently reviewed the current literature comparing dexametha sone and prednisone in pediatric asthma exacerbations. Both of these reviews concluded that, according to the literature, dexamethasone and prednisone are of equal effi cacy in treating pediatric asthma exacerbations, but both lacked the strength of using meta-analyses to confi rm those conclusions. Furthermore, Cross et al was written to address the use of these steroids in an outpatient setting, and both reviews failed to explain how to apply the evidence to the treatment of children in the hospital. The goal of the present review was to provide a more comprehensive evaluation of the evidence, including a metaanalysis comparing the effi cacy of dexamethasone with prednisone in the treatment of pediatric asthma exac erbations from a hospitalist's perspective.
METHODS
A Medline (January 1, 1965-January 11, 2014) search was conducted on January 12, 2014. It included clinical trials, systematic reviews, and comparative and observational studies using the search terms "dexamethasone AND asthma" and the Medical Subject Heading terms "infant OR child OR adolescent." The abstracts were reviewed for studies comparing the effi cacy of PO or intramuscular (IM) dexamethasone with prednisone/ pre dnisolone in the treatment of pediatric asthma exacerbations. A meta-analysis using a fi xed-effect model was performed on the data available from the studies regarding the rates of revisits to a health care provider. A separate meta-analysis was conducted to compare symptomatic improvement in the 2 groups after the initial ED visit.
RESULTS
The search returned 58 articles. Of these, 7 were found to be potentially relevant after preliminary abstract review and received full text evaluation. One of these was an ongoing study 24 and was excluded, leaving 6 articles for inclusion in our review.
Three of the studies investigated IM dexamethasone, and 3 studied PO dexamethasone ( Table 1 ). Primary outcomes differed between studies and included relapse rates, patient and/or parental report of the time until return to baseline activity, and changes in asthma scores. The studies also varied in the dose and duration of steroids, enrollment age, sample size, and study design.
IM Dexamethasone
Gordon et al 25 performed a prospective, randomized trial in pediatric patients with a history of asthma, defi ned as >2 respiratory illnesses requiring bronchodilator therapy who presented with wheezing. Patients received either a single dose of IM dexamethasone phosphate or 5 days of PO prednisolone. The 2 groups were matched on the basis of patient characteristics, asthma history, and objective measures of their acute presentation. Investigators compared the initial ED clinical asthma score and the score measured at a followup ED visit 96 to 120 hours later by an examiner blinded to group assignment. Children who received dexamethasone or prednisolone had no signifi cant difference in mean asthma score at day 4. This study's limitations included the exclusion of patients subjectively identifi ed to be too sick, potentially biasing toward the null. There was also potential bias in the lack of blinding 
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at the initial ED visit, although the physicians evaluating the subjects at the follow-up visit were appropriately masked.
Klig et al 26 performed a prospective, randomized pilot study comparing a single dose of IM dexamethasone with 3 days of PO prednisone in children with a history of >2 wheezing episodes and a mild to moderate asthma exacerbation based on a pulmonary index score. Age-and gendermatched patients were randomized to receive the medications. Five days later, patients were followed up either at the clinic or by telephone, and the parents reported any persistent symptoms and the need for further medical care. There were no differences identifi ed between groups in the number of patients who sought further medical attention during the 5-day follow-up period, parental report of symptoms 5 days after enrollment, or subsequent hospitalization. Limitations included the small sample size, lack of blinding during the initial ED visit, and the use of subjective parent-reports to assess improvement.
Gries et al 27 conducted a prospective, randomized, investigator-blinded study in patients aged 6 months to 7 years. The patients were given an initial asthma score, measuring symptoms of coughing and wheeze, and were then randomized to receive a single IM dexamethasone acetate injection or 5 days of PO prednisone. Parents of the patients kept an asthma symptom diary that included a clinical asthma score (based on frequency of wheeze and cough). Parents were telephoned intermittently to go over the symptom diaries and review the current asthma score. Patients were also evaluated in the clinic on day 5, and the asthma BID, twice daily; DEX, dexamethasone; max, maximum; OR, odds ratio; PIS, pulmonary index score; PSAS, patient self-assessment score. Although studies have shown that parents prefer a shorter course of corticosteroids 13 even if it requires IM injections, 29 this option is usually reserved for children who cannot take PO formulations or for whom IV access cannot be acquired. 30 The following studies compared PO corticosteroid preparations.
Oral Dexamethasone
Qureshi et al 31 performed the largest study to date comparing dexamethasone with prednisone. The study included pediatric patients with a history of asthma, defi ned as >2 wheezing episodes treated with bronchodilators and/or corticosteroids. Patients were randomized to receive either PO dexamethasone in the ED and were given a second, prepared dose to take 24 hours later, or PO prednisone, including a prescription for the fi nal 4 doses after the fi rst dose given in the ED. The primary outcome measure was relapse rate within 10 days, defi ned as an unscheduled medical provider visit for worsening or persistent symptoms. There was no signifi cant difference in relapse rates between the dexamethasone and prednisone groups. In addition to the lack of blinding, the major limitation of this study was the fact that children in the dexamethasone arm were provided a home dose on discharge, whereas those in the prednisone group were given a prescription to fi ll, potentially creating a discrepancy in adherence.
Altamimi et al 32 compared a single dose of PO dexamethasone with 5 days of PO prednisolone in a prospective, randomized, double-blind study. Patients with mild to moderate asthma were randomized to receive either dexamethasone or prednisolone in the ED, then discharged with 5 days of placebo or liquid prednisolone, respectively. Parents and patients completed a patient self-assessment sheet of asthma symptoms twice daily for 5 days, and patients were reevaluated in the ED on day 5. The number of days needed for the patient self-assessment sheet score to return to baseline was not signifi cantly different. Patients initially admitted from the ED were continued in the study and received the study medications. There was no difference in mean length of stay between groups (mean difference of 0.1, favoring prednisolone [confi dence interval [CI]: -0.56 to 0.76]). The major limitation of this study was the use of subjective scoring relying on parental interpretation of patient symptoms.
Greenberg et al
33 compared 2 daily doses of PO dexamethasone and 5 days of PO prednisone in preventing relapse for asthma exacerbations. In this prospective, randomized, double-blind study, children with a history of asthma were randomized to treatment, evaluated by using a pediatric asthma score, treated in the ED, and then sent home with either 1 more day of dexamethasone plus 3 days of placebo or 4 more days of prednisone. Patients received the medications in prepared blister packs before their discharge from the ED. The patients/families were contacted by telephone 10 days later and asked about relapse, defi ned as an unscheduled medical provider visit or hospitalization due to persistent or worsening asthma symptoms. There was no signifi cant difference in relapse rates between the dexamethasone and the prednisone groups (16% vs 8%, respectively; P = 0.27). The dexamethasone group had a slightly higher mean pediatric asthma score at presentation compared with the prednisone group (8 vs 6; P = .003), potentially explaining the higher relapse rate in the dexamethasone group, although this change was not statistically signifi cant. One limitation of this study is that ~50% of the patients were ultimately excluded (due mostly to admission or loss to follow-up).
Meta-analysis
A number of different outcome measures were reported in the 6 studies, but only 2 outcomes were consistently measured to be suitable for meta-analysis. The number of unscheduled physician visits after discharge was reported in all 6 studies. The pooled risk difference of 0.02 (95% CI: -0.02 to 0.05) favoring prednisone was not signifi cantly different (Fig 1) .
Four studies reported symptomatic improvement to baseline after the initial ED visit. Meta-analysis demonstrated no signifi cant difference between the dexamethasone and prednisone/ prednisolone groups (pooled risk difference of 0.98, favoring dexamethasone [95% CI: 0.71 to 1.35]) (Fig 2) .
Adverse Effects
In addition to comparing the effi cacy of dexamethasone versus prednisone,
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several of the studies' secondary outcomes evaluated adverse effects, especially vomiting. Findings were mixed. Qureshi et al 31 demonstrated signifi cantly more repeated vomiting in the ED in children in the prednisone group compared with the dexamethasone group (3% vs 0.3%; P = 0.008), but there was no difference in rate of vomiting at home (4% vs 2%; P = .17). Gordon et al 25 found 13% of their prednisolone group vomited at least once after taking the home medication. Alternatively, Greenberg et al 33 found no difference in rate of vomiting between patients given prednisone and dexamethasone in the ED (18% vs 10%; P = .27).
Compliance
The potential for better compliance with either the IM preparation or a shorter course of PO dexamethasone is largely touted as one of its benefi ts.
A few studies investigated compliance internal to their studies. Gries et al 27 measured parent-reported compliance of PO prednisone and found that 17% of children refused >75% of their prednisone doses, and 24% missed between 30% and 50% of their doses. Qureshi et al 31 found more patients in the prednisone group were noncompliant compared with the dexamethasone group (4% vs 0.4%; P = .004) due to lack of funds or forgetting to fi ll the prescription. However, this discrepancy may refl ect the study design in which the dexamethasone group received a dispensed second dose whereas the prednisone group had to fi ll a prescription.
DISCUSSION
The use of corticosteroids is standard of care for the treatment of asthma exacerbations and reduces the rate of hospitalization and relapse. [34] [35] [36] Despite variations in study design, medication formulation, dosing regimen, and sample size, none of the existing pediatric clinical trials found any differences when comparing dexamethasone and prednisone in treating mild to moderate asthma exacerbations. Furthermore, our metaanalysis demonstrated no difference in unscheduled physician revisits and symptomatic return to baseline after ED discharge.
In asthma, as with any other chronic illness, adherence to medication is critical. Numerous factors contribute to compliance. These include palatability, frequency of dosing, treatment course length, adverse effects, and cost. If dexamethasone is as effective as prednisone, then these other factors contribute to its potential benefi ts. Liquid dexamethasone has also been shown to be more palatable 21 incorporating costs of return ED visits or subsequent hospitalization, found 2 days of PO dexamethasone provided a predicted cost savings of $3500 to $7000 per 100 patients compared with 5 days of prednisone.
Currently, the data are encouraging, but fi ndings are mostly limited to small studies of mild to moderate asthma. None of these studies were true equivalence studies. Although recent reviews have been published regarding this question, 22, 23 this is the fi rst to use meta-analysis for certain outcome measures. If there is a minor benefi t of either therapy, smaller studies may not detect it (type II error). By including younger children with wheeze and cases of mild asthma that may otherwise have resolved without any corticosteroids, the results might not be extrapolated to children with acute, severe asthma, especially those requiring hospitalization. Furthermore, most studies excluded hospitalized patients. One small study by Ebrahimi and Sarkari 38 found that a single dose of IV dexamethasone (0.6 mg/kg) resulted in a shorter length of stay in hospitalized children with asth ma compared with 2 days of IV hydrocortisone. More evidence is required in the use of dexamethasone for patients hospitalized for asthma. One intriguing benefi t to the hospitalist is the potential to dispense a second dose in the hospital before discharge, thereby ensuring a high degree of compliance and obviating the need for a prescription, which as many as 33% to 65% of pediatric patients fail to have fi lled. 39, 40 A prospective, randomized controlled trial would be useful in evaluating these issues.
SUMMARY FOR THE PEDIATRIC HOSPITALIST
Formulation PO dexamethasone has a few diff erent preparations and concentrations available for children. Providers can crush dexamethasone tablets (2 or 4 mg) and mix it in liquid or food or use premade dexamethasone solution (0.5 mg/5 mL, 1 mg/mL). IV dexamethasone sodium phosphate (10 mg/mL) can also be given as an PO formulation. There have been studies demonstrating the ease and stability of giving IV dexamethasone sodium phosphate as an oral solution. 41 The benefi ts of using the IV formulation orally include ease of delivery rather than crushing tablets to constitute in solution and the lower volume compared with premixed solution (the IV form is 10-100 times more concentrated). This preparation's superior palatability compared with prednisolone has been confi rmed, 11,42 and the IV formulation given as an oral solution has been used in previous studies investigating dexamethasone treatment for bronchiolitis 43,44 and croup.
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Dosing
Each study of PO dexamethasone reviewed here used 0.6 mg/kg per dose, and all but 1 study investigated 2 daily doses. Collaboration between ED and inpatient providers is required for this regimen to be feasible in the hospital setting. Potentially, patients could be given the fi rst dose of the IV form orally in the ED on admission, and the second dose on the inpatient unit on hospital day 2, eliminating the need for a prescription at discharge.
CONCLUSIONS
There is growing evidence that a shorter course of dexamethasone is as effi cacious as prednisone in the treatment of mild to moderate asthma exacerbations in children presenting to the ED. However, a large, high-quality randomized controlled trial is needed to examine the role of dexamethasone versus prednisone in hospitalized children.
